In 2024, an estimated 310,720 women in the United States will be diagnosed with invasive breast cancer -- and about 80% of breast cancers are estrogen-receptor-positive, or ER+ breast cancer, making ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

After noticing concerning patient survival data across multiple clinical trials, the FDA is losing confidence in the safety profile of the notoriously toxic PI3K inhibitor drug class for blood cancers ...

We share the story of a pioneering and collaborative research programme at the ICR, initiated in the late 1990s, that led to one of the first clinical-stage PI3K inhibitors, laying the foundation for ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...